ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis

Streamlined analysis of 40 PFAS compounds in wastewater and soil

Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US) Environmental Protection Agency (EPA) Method 1633 (3rd draft). EPA Draft Method 1633 currently analyzes 40 PFAS compounds in wastewater and soil and is a complex and labor-intensive method, relying on multiple sample preparation and analysis steps. Success in running the technique depends on careful sample handling and the appropriate sample preparation supplies and instrumentation.

The new workflow synchronizes with the recent launch of the Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) system along with specific PFAS consumables, including the Agilent Bond Elut PFAS WAX Solid Phase Extraction (SPE) Cartridges, that provide the best recoveries while eliminating PFAS contamination and background, as well as the Agilent Infinity Lab PFC-free HPLC conversion kit, ‘PFAS-free’ Agilent vials and caps and other consumables. Specific data reporting needs for EPA 1633 are addressed through Agilent’s MassHunter Software, and sample tracking of the entire workflow can be done using the Agilent SLIMS Lab Management Platform enabling automation in data review and sample tracking which increases efficiency.

“PFAS are persistent, bioaccumulative, and of concern globally, with several countries looking to regulate them in water and soil. As a market leader in environmental analysis, Agilent is pleased to offer our customers a solution to achieve EPA Method 1633 performance requirements confidently,” explained Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division. “This new workflow simplifies setup and provides a robust end-to-end analytical methodology that reduces method development time, increases throughput and accuracy, allowing customers to focus on running critical samples.”

Agilent’s Bond Elut PFAS WAX SPE Cartridges are explicitly designed for PFAS analysis, providing excellent extraction performance and flow rates for a broad range of PFAS compounds while complying with stringent regulatory requirements. The cartridges undergo PFAS-specific QC testing to ensure optimal cleanliness and recovery, so customers can confidently isolate PFAS from environmental matrices, such as wastewater and soil.

SLIMS simplifies the intake of analytical requests and streamlines task management. Connected to the 6495 LC/TQ SLIMS guides users through the workflow and ensures the instrument, consumables, and reagents are fit for purpose. MassHunter software generates specific instrument data reports passing the information to SLIMS for evaluation of results and creation of the certificate of analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.